XBiotech Inc.
XBiotech Inc. (XBIT): 16 pipeline candidates · 2 upcoming catalysts · ~39 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
38.8 months
D/E 0.04 · 0% dilution
Lead: Phase 1/Phase 2
16 candidates
2 upcoming, next in ~27d
N/A
A transparent, data-derived signal for XBiotech Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$72.3M
Cash
$115.5M
Quarterly Burn
$9.0M
Runway
38.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (16 candidates)
| Drug | Phase |
|---|---|
| 514g3 plus standard iv antibiotic treatment | Phase 1/Phase 2 |
| anti-il-1a | Preclinical |
| anti-il-1a antibody | Preclinical |
| anti-infective antibody | Preclinical |
| anti-infective antibody cocktail | Preclinical |
| bermekimab | Phase 1 |
| c. difficile therapeutic | Preclinical |
| hutrukin | Phase 1 |
| influenza antibody cocktail | Preclinical |
| influenza therapeutic | Preclinical |
Showing 10 of 16 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Frequently asked questions
How many drug candidates are in XBiotech Inc.'s pipeline?
XBiotech Inc. (XBIT) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is XBiotech Inc.'s lead drug candidate?
XBiotech Inc.'s most advanced tracked candidate is 514g3 plus standard iv antibiotic treatment (Phase 1/Phase 2) for Staphylococcus Aureus Bacteremia.
What is XBiotech Inc.'s next catalyst?
XBiotech Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With " — expected July 15, 2026.
What is XBiotech Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, XBiotech Inc. has approximately 38.8 months of cash runway.
What is XBiotech Inc.'s market capitalization?
XBiotech Inc.'s market capitalization is approximately $72.3M.
Get the full picture on XBiotech Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.